🇺🇸

US SEC Filing Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — April 03, 2026

Proxy season is accelerating across NASDAQ-100 related filings with four companies (Mondelez, Aditxt, Camden National, Radian implied via comp) scheduling virtual annual meetings in May 2026, focusing on director elections, say-on-pay, auditor ratifications, and reverse splits. Period-over-period trends reveal stark contrasts: Token Communities suffered an 85% YoY revenue plunge to $356k, 87% drop in home sales, and gross margins shriveled 98% to $18k, while Mondelez reported solid 2025 net revenue growth and strong FCF amid cocoa volatility. Exec transitions signal caution—Intel's EVP/Chief Legal Officer exit effective June 1, 2026 (negative), contrasted by Radian's new Interim CFO compensation package ($500k base, $1M LTIP). Arcadia Biosciences' auditor switch highlights ongoing distress with going concern warnings and material control weaknesses from Dec 31, 2025 10-K. Lyell's S-3 enables resale of 1.95M shares from $25.61 milestone pricing (premium to $13.32 initial), potentially pressuring supply. Overall themes: resilient consumer staples (MDLZ) vs. biotech/small-cap distress (ADTX, LYEL, RKDA, TKCM), with limited capital allocation or insider trading signals but high event density for catalysts.

5 high priority 5 medium 10 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 03, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (though including diverse sectors), overarching themes include a heavy proxy season with 15+ annual/special meetings clustered in May 2026 (e.g., Valley National Bancorp May 18, Certara May 14), signaling routine governance but potential shareholder activism risks. Period-over-period trends reveal polarized performance: 6/12 companies with financial metrics showed YoY revenue growth averaging +22% (EACO +17.7%, Karman +36.6%), but margins mixed with compressions (Karman -290bps operating) and income declines (TCW Direct Lending -44% investment income); lending firms like TCW and Generation Income reported widening losses amid higher expenses. Forward-looking catalysts abound in April-May 2026: tender offer extensions (Lisata to Apr 13), spin-offs (First Tracks Apr 20), M&A approvals (Prosperity Bancshares-Stellar, European Wax going-private May 7), and Nasdaq hearings (Aeries, Twin Vee by Apr 9). Capital allocation highlights shareholder returns (GE Vernova doubled dividend to $2/share, +$3.6B buybacks/repurchases) contrasting debt stresses (Atlantic International defaults, United Homes covenant waivers). Insider activity sparse but neutral (no buys/sells flagged); sentiment mixed/neutral dominant (28/50 neutral), with financials like Valley National, Radian Group, FIS showing stable governance. Portfolio implications: overweight growth outliers like EACO/Karman, monitor delisting risks in small caps, and position for M&A catalysts in banks/insurers.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader context), proxy season dominates with 20+ DEF/DEFA14A filings signaling annual meetings in May 2026, highlighting mixed 2025 performance: solid adjusted metrics (e.g., Kraft Heinz adj EPS $2.60, Mondelez >$3B FCF target) amid GAAP challenges and cocoa volatility. Period-over-period trends show selective growth (McCormick strong vote approvals, Deluxe Data Solutions +31.3% YoY) but declines in others (Elventix cash -64.4%, Print -5.7%). Capital allocation leans positive with dividends declared (Alta Equipment $0.625/DS) and redemptions (Moog 2027 notes). CMBS trusts report uniform special servicer changes for Potomac Mills (8.9%-2.1% pool weights) and Essex loans to Torchlight/KeyBank, neutral but watch for loan distress. No widespread insider trading patterns; forward-looking includes Mondelez 3-5% organic growth long-term, Relmada Phase 3 mid-2026. Portfolio-level: 3/3 Staples firms (MDLZ, KHC, MKC) show resilient adj growth vs. sector headwinds, but mixed sentiment prevails. Actionable: Buy dips in staples on FCF strength; monitor CMBS for CRE risks spilling to staples supply chains.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Industrials stream (with some cross-sector context), proxy season dominates with 20+ DEF/DEFA14A filings highlighting robust 2025 performance in key industrials like GE Vernova (revenue +9% YoY to $38B, backlog $150B) and ITT Inc. (revenue +8% YoY to $3.9B, FCF $555M), amid capital returns exceeding $4B combined via buybacks and doubled dividends; however, small-cap distress signals emerge with delisting notices (Twin Vee, Matinas). Period-over-period trends show 3/5 detailed industrials with double-digit revenue/earnings growth (avg +10% revenue, +50% EBITDA), but REITs like Generation Income Properties report widening net losses (-31% YoY) and equity deficits. M&A activity accelerates (ITT's $4.8B SPX FLOW deal closed Mar 2026, Aurinia acquiring Kezar Q2 2026), while forward-looking catalysts cluster in May 2026 annual meetings and Q1 earnings (e.g., SouthState Apr 23). No widespread insider selling patterns, but neutral transitions/resignations in 10+ filings signal steady governance; capital allocation tilts bullish with $10B+ buyback authorizations. Portfolio-level, 7/10 high-materiality filings bullish on orders/backlogs, positioning industrials for reacceleration despite mixed bank/health crossovers.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 03, 2026

In a very quiet session for S&P 500 Energy with only one filing, Token Communities Ltd. (TKCM) 10-K dominates as the highest materiality event (9/10), revealing severe FY2025 operational distress with revenues crashing 85% YoY to $356,579 from $2.43M, home sales plunging 87% to $315k, gross margins contracting 98% to $18,499, and a net loss of $464k versus $1.28M profit prior year. Counterbalancing trends include total assets expanding 51% YoY to $6.04M, inventory surging 47% to $5.82M, cash jumping 142% to $62,841, and new construction in progress at $157k, signaling aggressive capacity buildup amid $157k investing cash outflow. Liabilities climbed 29% to $11.24M with a fresh $3.17M construction loan, widening the stockholders' deficit 10% to $5.20M from $4.74M, while shares outstanding held steady at 2.10B. Mixed sentiment stems from plummeting profitability versus asset/inventory expansion for potential rebound. No portfolio-level patterns emerge from the single filing, but TKCM's metrics highlight outlier distress in a sector context, with implications for turnaround potential if housing/energy-linked demand recovers, though leverage risks loom large.

1 high priority 1 total filings
· daily

US Material Events SEC 8-K Filings — April 03, 2026

Across the 50 filings from April 3, 2026, key themes include elevated executive churn (18 resignations/appointments/transitions, mostly neutral), aggressive financing maneuvers (15+ loans/amendments/raises amid tight liquidity), and a surge in M&A/SPAC activity (8 deals, particularly in biotech/pharma and energy, with positive sentiment in 6/8). Limited explicit period-over-period financials show no broad revenue/margin declines, but where present (e.g., TransAct rent -7% initially), cost savings emerge; forward-looking catalysts cluster in Q2 2026 (merger closes, tenders). Distress signals in 4 firms (defaults, waivers) contrast with bullish capital raises ($10M+ Entera Bio, $3M Mobix) and advisory extensions (Braemar). Portfolio-level: Biotech leads M&A (Aurinia-Kezar $110M+ implied value), real estate financing clusters (NexPoint $6M loan), signaling opportunistic growth amid leadership flux. Actionable: Prioritize M&A targets for takeout premiums, monitor covenant waivers for merger risks.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 03, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (with broader coverage including related small/mid-caps and SPACs), overarching themes include intense proxy season preparations for May 2026 annual meetings (15+ filings like GEV, BAC, Valley, EVgo), robust blue-chip growth (GE Vernova +9% YoY revenue to $38B, +213% net income to $4.9B; Bank of America +13% NI to $30.5B, +7% revenue to $113.1B), and elevated SPAC/M&A activity (12+ deals/extensions like OSRH license, Crown Reserve SPAC, ENVIRI $3.04B sale). Period-over-period trends reveal strong revenue expansion averaging ~25% YoY in reporting firms (Karman +36.6% to $471.5M, GEV +9%, BofA +7%) but mixed margins (Karman -290bps to 15.5%, NeOnc Q4 net loss +422% to $62.1M) and cash flow swings (Karman op cash -$22M vs +$26M YoY). Capital allocation favors shareholders at blue-chips (GEV dividend doubled to $2/share, buyback auth +$4B to $10B; BofA 28% TSR), while small caps face delisting risks (Twin Vee, Matinas). Portfolio-level patterns signal industrial/defense strength (record GEV $150B backlog), banking resilience, but biotech/delisting vulnerabilities; actionable now: buy blue-chip dips, avoid listing-threatened names ahead of catalysts.

33 high priority 17 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 03, 2026

The April 3, 2026, SEC filings reveal a dominant theme of proxy season kickoff with over 20 DEF 14A/DEFA14A filings scheduling May 2026 AGMs for director elections, say-on-pay, and auditor ratifications, signaling routine governance amid neutral sentiment. Strong performers include EACO (17.7% YoY Q2 sales growth to $117.8M, 44.9% net income surge), GE Vernova (9% YoY revenue to $38B, 213% net income to $4.9B), and LXP Industrial Trust (29.8% TSR, 97.1% occupancy +350bps YoY), highlighting industrial/defense resilience with robust backlogs and capital recycling. Mixed results prevail in REITs (Generation Income revenue -0.2% YoY, net loss widened to $6.4M) and small caps (BT Brands revenue -9% YoY but EBITDA +138%, Super League FY revenue -30% but cash to $14.4M). M&A/spin-off activity surges with Lisata tender extension to Apr 13, First Tracks spin-off distribution Apr 20, European Wax going-private vote May 7, and OSR's $815M milestone license deal targeting Apr 30 close. Portfolio-level trends show 5/12 reporting companies with >15% YoY revenue growth (avg +25%), but 4/12 with margin compression (avg -150bps); capital returns strong in GEV (dividend doubled to $2/share, buybacks +$4B auth). Risks cluster in debt covenants (Atlantic dispute, United Homes waivers) and delistings (Aeries), while opportunities lie in undervalued turnarounds and catalysts like May votes.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (though spanning broader sectors via 13Fs and trusts), dominant themes include a surge in proxy statements (15+ filings) for annual/special meetings in May-June 2026 focused on director elections, compensation votes, and auditor ratifications, signaling peak governance season. Financial trends show robust revenue/volume growth in outliers like AsiaFIN Holdings (+51.5% YoY revenue), Figure Technology (+102% YoY loan volume), and Bank of America (+13% YoY net income), but persistent margin compression (e.g., AsiaFIN -490bps gross margin) and covenant breaches (Flux Power EBITDA default). Key developments: First Tracks Biotherapeutics spin-off (Apr 20 distribution), Forian Inc. take-private at 22.6% premium (Q2 2026 close), multiple CMBS servicer switches to Torchlight, and financing expansions (e.g., Blue Owl $100M revolver). No major insider trading patterns noted (zero buys/sells detailed), limited capital allocation shifts (e.g., AFG $707M returns), and neutral sentiment overall (70% filings). Portfolio implications: Watch Consumer Discretionary proxies (YUM, Braemar) for stability amid sector volatility; alpha from spin-offs and M&A catalysts.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 03, 2026

Across 28 filings in the USA S&P 500 Healthcare stream (with broader financial context), proxy season dominates with 8+ AGMs scheduled for May 2026, highlighting governance focus amid executive transitions in biotechs (resignations, deaths, appointments). Biotech firms show cost-control measures like lease terminations (Kezar paid $1.3M fee), option repricings (Skye for 2.4M shares at $0.615), and auditor switches (Arcadia amid going concern issues), signaling cash preservation in a challenging environment. AbbVie slashed 2026 adj EPS guidance by $0.41 to $13.96-$14.16 due to $744M Q1 IPR&D expense, a major bearish signal for pharma; contrast with CVS Health's robust 2025 revenue of $402.1B and $10.6B op cash flow. Small biotechs like Elventix report deepening losses ($31k Q1, cash -64% to $890) and equity deficits, while HeartSciences faces leadership void post-COO death but reaffirms no operational disruption. No widespread insider buying/selling, limited capital returns data (American Financial returned $707M), and mortgage trusts show servicer changes without financial impacts. Portfolio trend: Neutral-to-mixed sentiment (12/28 neutral), with healthcare outliers in negative guidance/leadership risks vs positive large-cap performance; watch May catalysts for voting outcomes and earnings.

12 high priority 16 medium 28 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 03, 2026

Across 50 DEF 14A filings for 2026 proxy statements, a dominant theme is robust 2025 financial performance in industrials, REITs, and tech sectors, with 12 companies reporting revenue growth exceeding 10% YoY (e.g., GE Vernova +9%, CBRE +13.4%, ITT +8%) and strong capital returns via dividends and buybacks totaling billions (e.g., GE Vernova $3.6B returned, Royal Gold $1.2B since 2000). Margin expansions and FFO/NOI growth highlight operational resilience (e.g., LXP occupancy +350bps to 97.1%, Skyworks non-GAAP margin 24.4%), though food and select REITs show mixed results with GAAP declines amid volatility (e.g., NHI net income -3.5% YoY, Kraft Heinz GAAP EPS -$4.93). M&A activity surges as a catalyst (9 deals noted, including GE Vernova's $5.3B Prolec, ITT's $4.775B SPX FLOW), signaling consolidation and growth conviction. Capital allocation favors shareholders with dividend hikes (e.g., GE Vernova doubled to $2/share, Skyworks to $0.71) and buybacks, while forward-looking guidance points to sustained growth (e.g., Mondelez 3-5% organic revenue). Portfolio-level trends indicate outperformance vs. benchmarks (e.g., CBRE TSR beats S&P 500 across 1/3/5yr), but watch for say-on-pay votes and board refreshes at May-June 2026 meetings. Overall, bullish for industrials/REITs, neutral-mixed elsewhere, with alpha in M&A plays.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 03, 2026

The IPO Pipeline stream reveals a surge in activity with three new S-1 IPO filings (Auddia, VIDA Global, American Rebel) and two S-4 merger registrations (Prosperity Bancshares, Live Oak Acquisition Corp. V), highlighting a diverse mix of audio tech, AI, consumer holdings, banking, and SPAC de-SPAC plays amid a 2026 IPO resurgence. Overarching themes include pervasive execution risks like going concern opinions, Nasdaq compliance histories via reverse splits, founder voting controls exceeding 85%, and high redemption/dilution potentials, tempered by strategic M&A pursuits and committed financings such as $126.5M PIPE. Period trends show cash burn pressures (e.g., Auddia's $3.2M cash at Dec 31, 2025 despite $7.1M 2025 raise and $0.9M YTD to Mar 2026) contrasting with acquisition expansions (American Rebel's $20+MM in minority stakes). Mixed sentiments dominate (4/5 filings), with VIDA's positive outlook as the outlier in hot AI sector. Market implications point to volatile near-term pops for IPOs but elevated failure risks, regulatory bottlenecks as key catalysts, and opportunities in merger arb for fixed-ratio deals.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — April 03, 2026

Across 50 filings on April 3, 2026, dominant themes include financial distress in Indian companies (defaults totaling ₹366+ Cr across Dharani Sugars, Interworld Digital, Madhucon Projects; insolvencies at JCT Ltd and Baron Infotech) contrasting with robust US performance in defense/industrials (Karman Holdings revenue +36.6% YoY to $471.5M, backlog + to $801M; GE Vernova revenue +9% YoY to $38B, net income +213% to $4.9B). Margin pressures evident in Karman (-2.9 pts to 15.5%) and TCW Direct Lending (income -44% YoY), while capital allocation shines with GE Vernova's doubled dividend to $2/share and $10B buyback authorization. Neutral routine disclosures dominate Indian regulatory actions (no encumbrances in 7+ firms like Samkrg Pistons, Nutech Global), signaling promoter stability. Forward catalysts cluster in May 2026 annual meetings (Stereotaxis, Certara, NCR Atleos, GE Vernova) and April 7 RBI auction. Portfolio implications: Avoid Indian distress names, favor US growth outliers amid global high-priority events like M&A (Auddia exploring), mergers (United Homes pending May 31), and BTC trust launch.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 03, 2026

Across 12 US SEC filings in the Financial Results & Earnings stream, results reveal a bifurcated landscape with robust revenue growth in defense (Karman +36.6% YoY) and professional services (RCM +14.7% YoY, Concentrix +5.4% YoY, Ooma +7% YoY) offsetting sharp declines in lending/BDCs (TCW Direct -44% YoY, TCW VII -35.1% YoY), microcaps (Totaligent -99.5% YoY, Token -85% YoY), and others (POWERDYNE -7.2% YoY). Margin trends are mixed, with compression in 7/12 companies (e.g., Karman -2.9 pts, Concentrix operating -30% YoY) but improvements in adjusted EBITDA for Karman (+37%), Ooma (+46%), and RCM (+19%). Net losses narrowed in loss-making firms like GOOD GAMING (-75.5%), but cash burn persists in 8/12, with liabilities rising in 6/12 amid dilution and debt increases. Capital allocation shows shareholder focus via buybacks (RCM 114k shares, Concentrix 1k shares) and dividends (Concentrix $23M), signaling conviction in outperformers. Portfolio-level pattern: small-cap deterioration (8/12 revenue down avg -50% YoY) vs mid-cap resilience, implying rotation opportunities from distressed names to growth segments like defense/services. No insider activity or explicit guidance noted, but improving debt ratios (Karman 1.52 from 2.25) and backlog growth flag early recovery signals.

12 high priority 12 total filings
· daily

US SEC Trading Suspension Halt Orders — April 03, 2026

A cluster of five micro-cap companies across tech, AI, biotech, and marine sectors received delisting deficiency notices from Nasdaq and NYSE American between March 31 and April 2, 2026, signaling acute listing compliance pressures amid sustained low bid prices, equity shortfalls, and market value deficiencies. Common themes include bid price failures below $1 for 30 consecutive business days (e.g., Twin Vee post-1-for-10 reverse split in April 2025), stockholders' equity deficits (Matinas at $4.83M below $2M-$6M thresholds with 5-year losses; AEON at -$55M deficit with losses in 3/4 years), and MVPHS/MVLS shortfalls (Arrive AI below $15M/$50M). No positive period-over-period financial trends evident; instead, prolonged deficiencies (e.g., Aeries initial notice September 2025) indicate deteriorating compliance trajectories with no YoY equity recovery or bid price stabilization. All firms plan appeals or compliance plans, but ineligibility for extensions (e.g., Twin Vee, Aeries) heightens delisting risks, potentially leading to trading halts, OTC transfers, and shareholder value erosion. Portfolio-level pattern: 5/5 companies show negative sentiment (4/5 outright negative, 1 mixed), with biotechs overrepresented in equity failures; investors face liquidity risks in small caps. Critical implication: Imminent catalyst calendar of hearings and plans could trigger suspensions, advising avoidance or short positioning.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 03, 2026

The 39 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in exchange compliance failures, with 5 companies (Aeries Technology, Twin Vee PowerCats, Matinas BioPharma, Arrive AI, AEON Biopharma) receiving delisting notices due to bid price, MVPHS/MVLS, and stockholders' equity deficits below $2M-$6M thresholds as of Dec 31, 2025, signaling acute distress in microcap/biotech names. Covenant waivers and amendments dominate (United Homes, Firefly Aerospace, Fluence Energy, KORU Medical), often tied to mergers or liquidity covenants, providing short-term relief but with strings like refinancing deadlines (e.g., May 31, 2026 for United Homes). Positive offsets include M&A (Aurinia/Kezar merger Q2 2026, Forian $68M buyout, Soluna wind farm acquisition), debt cancellations (Nukkleus $16M), and equity raises (Entera Bio $10M, Vivos $4M), though many are dilutive (Mobix Labs 15% discount convertible, Interactive Strength Series C issuance). No uniform YoY/QoQ trends due to event-driven filings, but recurring low equity ($4.83M Matinas vs $6M req, -$55M AEON) and reverse splits (FibroBiologics 1:20) highlight deteriorating balance sheets. Portfolio-level: 15/39 negative/mixed sentiment, clustered in biotechs/small caps; implications include elevated bankruptcy risk but alpha in merger-arbitrage and post-financing turnarounds.

39 high priority 39 total filings
· daily

US Executive Officer Management Changes SEC — April 03, 2026

Across 38 SEC filings on US executive and director changes from April 3, 2026, the dominant theme is high turnover with over 25 resignations/departures (mostly directors and CFOs) stated as not due to disagreements, indicating routine board refreshes rather than operational distress; healthcare/biotech saw 9 events (e.g., COO death at HeartSciences, CFO appointments). Positive retention signals in 7 filings include $41.5M LTRP at MercadoLibre, $5M+ equity awards at ETHZilla, and $528k bonuses at Gibraltar, with no performance declines reported across multiple firms. Negative outliers include covenant breach threats and COO termination at Atlantic International (debt <$50M disputed as satisfied) and Intel's CLO exit. Period-over-period trends show stable metrics (no YoY/QoQ declines noted in 15+ filings), with forward-looking stability via reaffirmed guidance at WW International and 2026 bonus metrics at MercadoLibre. Portfolio implications: small-cap leadership stability supports hold; monitor finance/healthcare for transition risks amid neutral sentiment (26/38 neutral).

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 03, 2026

Across 38 SEC filings on USA Board Room Changes dated around April 3, 2026, the dominant theme is leadership stability amid 25+ neutral resignations (explicitly not due to disagreements), balanced by 10+ appointments/promotions and retention incentives like equity awards totaling $46M+ (e.g., MercadoLibre LTRP $41.5M, ETHZilla CEO $4.3M). Positive developments in 7 filings highlight management alignment via bonuses (Gibraltar $528K total), option repricings (Skye 2.42M shares), and experienced hires (e.g., Rhythm's Kim Popovits with 40+ years biotech), while negatives are limited to 2 cases: Atlantic's default notices threatening management replacement and HeartSciences COO death. No broad period-over-period deteriorations reported (e.g., 'no performance declines' in 5 filings), with forward-looking reaffirmations (WW guidance intact) signaling continuity; healthcare/biotech shows 8 changes vs tech/finance 12, implying sector-neutral churn. Portfolio-level, 70% neutral sentiment suggests low disruption risk, but high materiality (avg 6/10) in C-suite shifts warrants monitoring for execution gaps. Implications: Bullish for retention-focused firms, cautious on small-caps with disputes.

38 high priority 38 total filings
· daily

US Merger & Acquisition SEC Filings — April 03, 2026

The six SPAC filings reveal a bifurcated US M&A landscape with fresh momentum in de-SPAC transactions and IPOs contrasted by compliance distress and financing strains; Crown Reserve's Carvix merger and Future Money's $115.6M IPO (including $112M public + $3.04M private placement) signal robust deal activity, while JENA's NYSE non-compliance and DMII's sponsor transition highlight sector headwinds. No explicit YoY/QoQ financial trends or operational metrics reported across filings, but forward-looking timelines cluster catalysts in 45 days (JENA plan), 4-6 months (DMII deal execution), and 3-year earnouts (Crown). Insider activity absent; capital allocation focused on trust deposits (Future Money) and debt amendments (Inflection Point note up 14% QoQ from $700k to $800k). High materiality developments (avg 7.5/10) underscore SPAC revival potential amid regulatory risks, with positive sentiment in 2/6 filings driving takeover opportunities. Portfolio-level pattern: 4/6 newly published filings show financing/de-SPAC urgency, implying accelerated M&A timelines versus stagnant peers.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 03, 2026

Overnight SEC filings reveal a proxy season kickoff with 15+ companies scheduling May 2026 annual meetings for director elections, auditor ratifications, and say-on-pay votes, largely neutral but signaling governance stability amid mixed small-cap earnings. Period-over-period trends show revenue growth in outliers like EACO (+17.7% YoY Q2 sales to $117.8M, +44.9% NI), Karman Holdings (+36.6% FY2025 rev to $471.5M), and GE Vernova (+9% rev to $38B, +213% NI to $4.9B), but margin compression in 5/10 reporting firms (e.g., Karman -2.9 pts to 15.5%, BT Brands EBITDA +138% despite rev -9%). Capital allocation highlights shareholder returns at GEV (dividend doubled to $2/share, buybacks auth +$4B to $10B) and Alta Equipment ($0.625/dividend on preferred). M&A/spin-off catalysts include First Tracks spin-off (Apr 20 distro), European Wax going-private vote (May 7), and Lisata tender extension to Apr 13. Risks cluster around debt disputes (Atlantic International lawsuit) and covenant waivers (United Homes merger-pending), while positives emerge in licensing (OSR $815M milestones) and transformations (Super League debt-free, Q1 2026 rev beat expected). Portfolio implications favor monitoring defense/healthtech growth and May proxy-driven volatility, with small-cap mixed results tempering broad rallies.

13 high priority 21 medium 34 total filings